| |
| |
|
| Insider
Information: |
Coughlin Timothy P |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
190,353 |
|
|
Indirect Shares
|
62,390 |
|
|
| Direct
Value |
$19,022,456 |
|
|
|
Indirect Value
|
$216,480 |
|
|
| Total
Shares |
252,743 |
|
|
| Total
Value |
$19,238,936 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -74.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Chief Financial Officer |
2017-02-06 |
137,961 |
|
0 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Director |
2023-05-17 |
42,500 |
2015-03-31 |
0 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director |
2022-06-09 |
9,892 |
2022-06-09 |
56,390 |
Premium* |
|
|
aTyr Pharma Inc |
LIFE |
Director |
2023-05-17 |
0 |
2023-05-17 |
6,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LIFE |
aTyr Pharma Inc |
Director |
– • – |
2023-05-17 |
4 |
GA |
$0.00 |
$0 |
I/I |
6,000 |
6,000 |
0 |
- |
|
| LIFE |
aTyr Pharma Inc |
Director |
– • – |
2023-05-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,000 |
0 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
42,500 |
0 |
- |
|
| LIFE |
aTyr Pharma Inc |
Director |
– • – |
2023-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
9,892 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.81 |
$32,824 |
D/D |
(1,439) |
57,632 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2022-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
38,000 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,681 |
59,071 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
35,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
32,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
29,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2018-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
27,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
24,500 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2017-02-06 |
4 |
AS |
$43.14 |
$41,544 |
D/D |
(963) |
137,961 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2017-02-03 |
4 |
AS |
$42.55 |
$63,825 |
D/D |
(1,500) |
136,324 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2017-01-17 |
4 |
AS |
$40.65 |
$71,138 |
D/D |
(1,750) |
134,824 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2017-01-10 |
4 |
AS |
$43.37 |
$75,898 |
D/D |
(1,750) |
133,124 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2016-11-23 |
4 |
B |
$2.66 |
$149,997 |
D/D |
56,390 |
56,390 |
2.39 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2016-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
22,000 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2016-02-03 |
4 |
AS |
$38.06 |
$57,090 |
D/D |
(1,500) |
131,374 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2016-01-19 |
4 |
AS |
$46.69 |
$81,708 |
D/D |
(1,750) |
129,874 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2016-01-11 |
4 |
AS |
$44.25 |
$77,438 |
D/D |
(1,750) |
128,124 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2015-10-16 |
4 |
AS |
$47.78 |
$1,194,500 |
D/D |
(25,000) |
126,374 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2015-07-20 |
4 |
AS |
$55.00 |
$1,100,000 |
D/D |
(20,000) |
101,374 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2015-07-20 |
4 |
OE |
$5.76 |
$115,200 |
D/D |
20,000 |
121,374 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
